Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00467389 |
The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.
Condition | Intervention | Phase |
---|---|---|
Cocaine Abuse and Dependence |
Drug: Donepezil, 5 mg daily |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Donepezil Effects on Cocaine Craving and Pharmacokinetics |
Estimated Enrollment: | 42 |
Study Start Date: | February 2007 |
Study Completion Date: | September 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Drug: Donepezil, 5 mg daily |
This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of cocaine will be preceded or followed by administration of intravenous placebo (saline) in a random order.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Department of Veterans Affairs ( Grasing, Kenneth - Principal Investigator ) |
Study ID Numbers: | NEUA-014-05S |
Study First Received: | April 27, 2007 |
Last Updated: | October 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00467389 |
Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
Acetylcholine Acetylcholinesterase Butyrylcholinesterase Cholinesterase Inhibitor |
Cocaine-Related Disorders Mental Disorders Donepezil Substance-Related Disorders |
Disorders of Environmental Origin Acetylcholine Cocaine |
Nootropic Agents Cholinesterase Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Physiological Effects of Drugs Enzyme Inhibitors Cholinergic Agents Central Nervous System Agents Pharmacologic Actions |